After a long, hard battle with the FDA, Sarepta Therapeutics is now ready to submit a rolling New Drug Application (NDA) for eteplirsen to treat boys with Duchenne muscular dystrophy (DMD) amenable to exon-51 skipping therapy (about 13% of DMD boys).
Carcinoid syndrome is a rare condition that often is often difficult to diagnose and manage. A key person in the management of patients with carcinoid syndrome is the oncology nurse.
Pablo Lapuerta, MD, chief medical officer at Lexicon Pharmaceuticals discusses the pathophysiology of carcinoid syndrome, a rare condition that can take years to properly diagnose.
April is Fabry Disease Awareness Month. Fabry disease is an inherited lysosomal disorder that primarily affects males.
Currently, no FDA-approved treatments are available for rare mitochondrial myopathies.
Sarepta Therapeutics has announced that Chris Garabedian has resigned as President, Chief Executive Officer (CEO), and as a member of the Board of the company, effective immediately. Edward Kaye, MD, the company’s Chief Medical Officer (CMO) will act as interim CEO.
Patient perspectives generate specific outcome objectives, what they are willing to do to achieve them, the risks they are willing to bear, and the costs they are willing to pay. The same could be said about payers.
Merck announced that they are stopping their head to head comparative phase 3 study in advanced melanoma early since they met their primary endpoint ahead of schedule. In the competitive world of big pharma, that is considered a slam dunk.
The study’s primary endpoint—rate of complete remission (CR)—was not significantly different between the two groups.
Endo International has confirmed they are offering to pay $175 per share (i.e., $11 Billion) or an 11% premium over the offer made by Valeant.
External Resources

MJH Associates
MD Magazine
Pharmacy Times
Specialty Pharmacy Times
Physicians' Education Resource
Internal Resources

Connect With Us:

About Us
Contact Us
Privacy Policy
Terms and Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Rare Disease Report 2015
Intellisphere, LLC. All Rights Reserved.